We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...

Summit Therapeutics Inc (SMMT) reports a robust cash reserve and debt-free status, while advancing key clinical trials and ...

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

ORMOND BEACH, FLORIDA / ACCESSWIRE / February 25, 2025 / NOK Therapeutics, Inc., a biotech firm dedicated to developing novel immunotherapies leveraging NK cell ...

Plasma p-tau217 can be measured using a simple blood test, providing patients and their physicians with an important tool they can use to tailor their personalized treatment regimens.” The Hanson Wade ...

Summit Therapeutics Inc. (NASDAQ: NASDAQ: SMMT) stock climbed 5% after the biopharmaceutical company announced a clinical ...

Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunovant (IMVT – Research Report), Summit Therapeutics ...

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.